ClinicalTrials.gg
RecruitingNCT07366164SIMPLYUpdated Nov 9, 2026

Hemodynamic Optimization Using an Artificial Intelligenze System

An interventional study of assisted fluid therapy in Hemodynamic (MAP) Stability and Fluid Management, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 9, 2026Primary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will investigate the impact of using an automated fluid management system on intraoperative fluid therapy in patients undergoing colorectal surgery. The aim is to evaluate whether automated guidance can optimize hemodynamic stability and reduce the incidence of arterial hypotension,

02

Conditions studied

  • Hemodynamic (MAP) Stability
  • Fluid Management
03

In context

Lead sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS is the lead sponsor of 953 studies on the registry; 541 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- patients >18 years old and ASA 3 scheduled for laparoscopic colorectal surgery

Exclusion criteria

Exclusion Criteria:

  • Refusal of consent
  • > 35 kg/m2
  • urgent cases
  • pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    treatment group

    fluid therpay fo this grioup will be giuded through the assisted fluid management system

    Device: assisted fluid therapy

  • No intervention
    control group

    patients belonging to this group will receive fluids following a standard hemodynamic protocol

Interventions

  • Deviceassisted fluid therapy

    for this intervention, fluids will be administered using an assisted fluid device

06

What researchers measure

Primary outcomes

  1. amounts of fluids

    the amounts of administered fluids after surgery will be registered and compared

    Time frame: at the end of surgery

07

Study locations

1 of 1 sites recruiting
  • Fondazione Policlinico Universitario Policlinico Gemelli
    Roma, RM 00166, Italy
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2025 to primary completion in Jun 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Jan 26, 2026
StartActual
Oct 1, 2025
Primary completionActual
Jun 1, 2026
CompletionEst.
Jan 1, 2027
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • Descriptionamounts of fluids: how it is measured was reworded
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • Descriptionamounts of fluids: how it is measured was reworded
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07366164
Responsible party
RUSSO ANDREA (Principal Investigator, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) — Principal investigator
First posted
Jan 26, 2026
Start date
Oct 1, 2025
Primary completion
Jun 1, 2026
Completion
Jan 1, 2027 (estimated)
Last update
Nov 9, 2026

Study contacts

andrea russo, medical doctor
Contact
russoandreamd@gmail.com
+393333926815
Paola Aceto, professor
Contact
paola.aceto@policlinicogemelli.it
andrea russo
principal investigator · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion